Treatment of metastatic colorectal cancer has continued to evolve over the last several years, with emerging identification of biomarkers that underlie heterogeneity of responses to new and existing therapy. Ongoing clinical research seeks to identify new therapeutic options in molecularly-defined subgroups of patients. We will review the most exciting and clinically impactful research findings in this presentation.